Anti-HIV agents. Maraviroc--coming soon.
D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use*; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use; D011753:Pyrones / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load
D003510:Cyclohexanes; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D010919:Placebos; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D014230:Triazoles; D000077560:Enfuvirtide; D000077592:Maraviroc; D019438:Ritonavir; C107201:tipranavir